• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail

Vesicare (Solifenacin Succinate) Tablets

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – August 2012

Summary View

 

ADVERSE REACTIONS

Post-Marketing Experience
  • Eye disorders: glaucoma
  • Gastrointestinal disorders: gastroesophageal reflux disease and ileus
  • Respiratory, thoracic and mediastinal disorders: dysphonia